DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
TUXEDO-3
Subanalysis: Outcome of patritumab deruxtecan (HER3-DXd) in patients with HER2-positive metastatic breast cancer and CNS involvement previously treated with T-DXd: A subanalysis of TUXEDO-3
BREAST
SABCS
2025
ADELA
TPS 43 - ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
BREAST
MBCC
2025
I3LUNG
An Ensemble Approach to Predict Three-Class PD-L1 Expression from H&E Whole-Slide Images
LUNG
WCLC
2025
LUZERN
LUZERN: Phase 2 trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer
BREAST
Cancers
2025
DEBBRAH
Trastuzumab deruxtecan in patients with leptomeningeal carcinomatosis from HER2-positive and HER2-low advanced breast cancer: The DEBBRAH Trial
BREAST
(Journal) Med
2025
I3LUNG
I3LUNG-PDSS: A Multimodal AI-Based Clinical Decision Support System for Predicting Immunotherapy Efficacy in Metastatic NSCLC
LUNG
WCLC
2025
I3LUNG
Exploring the Potential of Multimodal Cough Analysis as a Pre-Screening Tool for Non-Small Cell Lung Cancer Detection
LUNG
WCLC
2025
ROSHER
Real-World Data of Clinicopathological Characteristics and Management of Patients With HER2+ Breast Cancer
BREAST
ESMO Open
2025
REPOSE
A Phase II Study of Repotrectinib in ROS1-positive non-Small Cell Lung CancerPatients with Active Brain Metastasis - REPOSE
LUNG
WCLC
2025
PHERGAIN
Subanalysis- MRI vs PET: Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2[+] early breast cancer patients: An unplanned exploratory analysis of PHERGain trial
BREAST
ESMO Open
2025
WIN-B
Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor DEBIO 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): the WIN-B study
BREAST
ASCO
2025
Pooling DEBBRAH-Tuxedo
Results of a Patient-Level Pooled Analysis of Three Studies of Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with Active Brain Metastases
BREAST
ESMO Open
2025
Other MEDSIR related articles
